Click here to view Webcast
This educational activity is specifically designed for medical and surgical oncologists, dermatologists, researchers and other physicians, physicians-in-training and other healthcare professionals interested in and/or involved in the care of patients with melanoma and its consequences.
This Webcast is a direct representation of the Perspectives in Melanoma XI meeting held in Huntington Beach, California on October 3-4, 2007. The history of melanoma treatment, drug development, staging and diagnostics, as well as recent exciting clinical trial results are the emphasis of this very thorough online activity. International experts define where we have been and where we are going with the treatment of this elusive disease.
After completing this activity, the participant will be able to:
- Discuss important aspects of the pathogenesis of melanoma
- Identify pathways involved in melanoma progression and their implications for potential therapy
- Integrate important advances in diagnostic and imaging technologies into clinical practice
- Describe emerging concepts and progress in the role of surgery and staging of melanoma
- Analyze recent progress in melanoma vaccine development
- Describe the role of the immune system in melanoma pathogenesis and identify immunological targets for therapy
- Identify currently available and investigational targeted agents for the management of metastatic melanoma
- Incorporate findings from recent clinical trials examining the role of adjuvant therapy into daily management of patients with melanoma
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex®, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are encouraged to provide a balanced view of therapeutic options by utilizing generic names of several to ensure impartiality.
All faculty participating in an Imedex activity are required to disclose commitments to and/or relationships with pharmaceutical companies, biomedical device manufacturers or distributors, or others whose products or services may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support
| Boris C. Bastian, MD |
Abbott Molecular1 |
| Lisa H. Butterfield, PhD |
National Institute of Health1, National Cancer Institute Foundation1 |
| Alexander M.M. Eggermont, MD, PhD |
Boehringer-Ingelheim Pharmaceuticals, Inc2; FSK Bio2; Genta2; MERCK & CO., Inc.1; Novo-Nordisk A/S2; NovaRx Corporation2; Sanofi-Pasteur SA2 |
| Keith T. Flaherty, MD |
Bayer HealthCare Corporation/Onyx Pharmaceuticals2, Genentech BioOncology2, Novartis Pharmaceuticals Corporation2, Plexxikon, Inc.2 |
| John M. Kirkwood, MD |
Eleos Incorporated2, Intrexon Corporation2 |
| Kim A. Margolin, MD |
Bristol-Myers Squibb Company1,3, Medarex Inc1,3, Novartis Pharmaceuticals Corporation1,3 |
| Steven J. O’Day, MD |
Bristol-Myers Squibb Company1,3 |
| Aleksandar Sekulic, MD, PhD |
Agilent Technologies1 |
| Craig L. Slingluff, Jr, MD |
Berlex Laboratories, Inc1, Bristol-Myers Squibb Company2; Immatix2 |
| Charles D. Surh, PhD |
Johnson & Johnson2 |
| Richard Wahl, MD |
GE Pharmaceuticals1; Medi-Physics Co., Ltd.2; National Institute of Health1; NIHON Pharmaceuticals Co., Ltd.2; Threshold Pharamaceuticals2; TransMolecular, Inc.1 |
The following speakers have reported an affiliation with the supporters of this conference:
| Alexander M.M. Eggermont, MD, PhD |
Schering-Plough Corporation1,2, Synta Pharmaceuticals Corp.2 |
| Keith T. Flaherty, MD |
AstraZeneca Pharmaceuticals LP2, Schering-Plough Corporation2 |
| Helen Gogas, MD |
Schering-Plough Corporation2 |
| John M. Kirkwood, MD |
Bristol-Myers Squibb Company1, Pfizer Inc1, Schering Plough Corporation3 |
| Steven J. O’Day, MD |
Synta Pharmaceuticals Corp1,2 |
| Vernon K. Sondak, MD |
Schering Biotech Oncology3 |
The following speakers do not report any affiliation:
Dorothea Becker, PhD
Esteban Celis, MD, PhD
Soheil S. Dadras, MD, PhD
Adil I. Daud, MD
Christine S. Falk, PhD
Thomas Gajewski, MD, PhD
Jeffrey E. Gershenwald, MD
Julia Newton-Bishop, MD
Peter T.C. So, PhD
John F. Thompson, MD
Hua Yu, PhD
All materials are included with the permission of the authors.
All Imedex staff members who are in a position to control the content of this activity have no financial relationships with any commercial interests that are relevant to this activity.
|
|
Boris C. Bastian, MD
University of California San Francisco Cancer Center
San Francisco, California
Dorothea Becker, PhD
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania
Lisa H. Butterfield, PhD
University of Pittsburgh
Pittsburgh, Pennsylvania
Esteban Celis, MD, PhD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Soheil S. Dadras, MD, PhD
Stanford School of Medicine
Stanford, California
Adil I. Daud, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Alexander M.M. Eggermont, MD, PhD
Erasmus University Medical Center
Daniel Den Hoed Cancer Center
Rotterdam, The Netherlands
Christine S. Falk, PhD
University of Heidelberg
Heidelberg, Germany
Keith T. Flaherty, MD
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania
Thomas Gajewski, MD, PhD
University of Chicago
Chicago, Illinois
Jeffrey E. Gershenwald, MD
M. D. Anderson Cancer Center
Houston, Texas
Helen Gogas, MD
University of Athens
Athens, Greece
Valerie Guild
Charlie Guild Melanoma Foundation
Richmond, California |
John M. Kirkwood, MD
University of Pittsburgh Medical Center
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania
Kim A. Margolin, MD
City of Hope Comprehensive Cancer Center
Duarte, California
Julia Newton-Bishop, MD
Cancer Research UK
St. James’s University Hospital
Leeds, United Kingdom
Steven J. O’Day, MD
The Angeles Clinic and Research Institute
Los Angeles, California
Aleksandar Sekulic, MD, PhD
Mayo Clinic
Scottsdale, Arizona
Craig L. Slingluff, Jr, MD
University of Virginia
Charlottesville, Virginia
Peter T.C. So, PhD
Massachusetts Institute of Technology
Cambridge, Massachusetts
Vernon K. Sondak, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Charles D. Surh, PhD
The Scripps Research Institute
La Jolla, California
John F. Thompson, MD
University of Sydney
Sydney, Australia
Richard Wahl, MD
Johns Hopkins University
Baltimore, Maryland
Hua Yu, PhD
City of Hope Comprehensive Cancer Center
Duarte, California |
This activity is sponsored by Imedex, LLC.
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum of 12.25 AMA PRA Category 1 Credits™.
Physicians should only claim credit commensurate with the extent of their participation in the activity.
In order to receive credit, participants must successfully complete the post-test and complete the online evaluation form. You will receive an online CME statement of credit to print for your records.
For questions regarding the accreditation of this activity, please contact
Imedex
4325 Alexander Drive
Alpharetta, GA 30022
Fax: +1(770) 751-7334
Email: enduring@imedex.com
This Webcast may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.
The opinions expressed in this Webcast are the opinions of the authors and do not necessarily reflect the opinions of Imedex.
The following companies have provided unrestricted educational grants in support of this activity: AstraZeneca Pharmaceuticals LP/Abraxis Oncology, Pfizer Inc, Roche Laboratories Inc, Schering-Plough Corporation, and Synta Pharmaceuticals.
Click here to view Webcast
|
